RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects

Abroad (travel likely)RecruitingPHASE2

Conditions

NMIBC

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Peking University First Hosptital, Beijing, Beijing Municipality, China
Contact: Study coordinator (Zhisong He, Doctor) · wyj7074@sohu.com · 13910688432

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Bladder-Sparing Treatment Strategies of Large-Volume Non-Muscle-Invasive Bladder Cancer

Bladder Cancer · NMIBC

Abroad (travel likely)Recruiting

Nanjing, China

Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer

Non-Muscle-Invasive Bladder Cancer (NMIBC)

Abroad (travel likely)RecruitingPHASE2

Taiyuan, China

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Bladder Cancer · Non-Muscle Invasive Bladder Cancer (NMIBC) · Urothelial Carcinoma

Abroad (travel likely)RecruitingPHASE2

Iowa City, United States

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

NMIBC

Abroad (travel likely)RecruitingPHASE1, PHASE2

Chandler, United States · Sacramento, United States